Zhou, Jie; Bie, Jianbo; Wang, Xiaoyu; Liu, Quan; Li, Rongcui; Chen, Hualong; Hu, Jinping; Cao, Hui; Ji, Wenming; Li, Yan; Liu, Shuainan; Shen, Zhufang; Xu, Bailing published the artcile< Discovery of N-Arylsulfonyl-Indole-2-Carboxamide Derivatives as Potent, Selective, and Orally Bioavailable Fructose-1,6-Bisphosphatase Inhibitors-Design, Synthesis, In Vivo Glucose Lowering Effects, and X-ray Crystal Complex Analysis>, Related Products of 89003-95-2, the main research area is T2MD liver FBPase inhibitors glucose lowering crystal structure binding.
Liver fructose-1,6-bisphosphatase (FBPase) is a key enzyme in the gluconeogenesis pathway. Inhibiting FBPase activity represents a potential treatment for type 2 diabetes mellitus. A series of novel N-arylsulfonyl-4-arylamino-indole-2-carboxamide derivatives have been disclosed as FBPase inhibitors. Through extensive structure-activity relationship investigations, a promising candidate mol. Cpd118 [sodium (7-chloro-4-((3-methoxyphenyl)amino)-1-methyl-1H-indole-2-carbonyl] [(4-methoxyphenyl)sulfonyl)amide](I) has been identified with high inhibitory activity against human liver FBPase (IC50, 0.029 ± 0.006 μM) and high selectivity relative to the other six AMP-binding enzymes. Importantly, Cpd118 produced significant glucose-lowering effects on both type 2 diabetic KKAy mice and ZDF rats as demonstrated by substantial reductions in the fasting and postprandial blood glucose levels, as well as the HbA1c level. Furthermore, Cpd118 elicited a favorable pharmacokinetic profile with an oral bioavailability of 99.1%. Moreover, the X-ray crystal structure of the Cpd118-FBPase complex was resolved, which revealed a unique binding mode and provided a structural basis for its high potency and selectivity.
Journal of Medicinal Chemistry published new progress about Bioavailability. 89003-95-2 belongs to class bromides-buliding-blocks, and the molecular formula is C8H4BrNO, Related Products of 89003-95-2.
Referemce:
Bromide – Wikipedia,
bromide – Wiktionary